General Clinical Chemistry Analyzers and Accessories
Abcam Apremilast, 25MG
MW 460.5 Da, Purity >98%. Ppotent PDE4 (phosphodiesterase 4) inhibitor (IC₅₀ = 74 nM). It reduces TNF-α production in human synovial cells and significantly suppresses experimental arthritis.
The product is subject to the following: Abcam Restricted Use Statement
Abcam V x -745, p38 alpha MAPK inhibitor, 5MG
MW 436.3 Da. Potent, selective p38 alpha MAPK inhibitor (IC₅₀ = 10 nM), with 20-fold selectivity over p38 beta and 1000-fold selectivity over closely related kinases, ERK1 and JNK1-3.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SB742457 (Intepirdine), 5-HT6 antagonist, 5MG
MW 353.4 Da. Potent (pKi = 9.63) and highly selective 5-HT6 antagonist. Greater thsan 100-fold selective against other receptors. Reverses learning impairment in animal models.
The product is subject to the following: Abcam Restricted Use Statement
Abcam BIIB 021, 5MG
MW 318.76 Da, Purity >98%. Selective, Hsp90 competitive inhibitor (Ki = 1.7 nM). Displays no significant activity at a range of ATP-binding kinases or Na+K+ ATPase. Induces degradation of HER-2 in vitro (EC₅₀ = 38 nM in MCF-7 cells). Inhibits growth and promotes cell death in a variety of human tumor cells. Orally bioavailable.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Alvespimycin (17-DMAG) hydrochloride, 100MG
MW 653.2 Da, Purity >99%. A potent Hsp90 inhibitor (IC₅₀ = 62 nM), can bind to the ATP-binding motif and inhibit the protein chaperoning activity.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Ponesimod, sphingosine-1-phophate receptor agonist, 5MG
MW 461 Da. Ponesimod is a potent agonist of sphingosine-1-phophate receptor. (S1P₁/EDG-1; IC₅₀s = 6, >10,000, 2,068, 1,956, and 142 nM for S1P₁-S1P₅, respectively, in a radioligand binding assay). Selectively activates S1P₁ in a GTPγS assay (EC₅₀s = 5.7, >10,000, 105, 1,108, and 59.1 nM, for S1P₁-S1P₅, respectively).
The product is subject to the following: Abcam Restricted Use Statement
Abcam URMC-099, 25MG
MW 421.5 Da, Purity >98%. Novel orally bioavailable, brain penetrant mixed lineage kinase (MLK) inhibitor (IC₅₀ values of 19, 42, 14, and 150 nM for MLK1, MLK2, MLK3, and the related MLK family member DLK, respectively). Inhibits multiple kinase pathways including LRRK2 (IC₅₀ = 11 nM). Decreases the production of inflammatory cytokines in cultured microglia exposed to HIV-1 Tat. Reduces fMLP-induced chemotaxis of neutrophil from wild-type C57Bl/6 mice. Facilitates Amyloid-β Clearance in a Murine Model of Alzheimer's Disease.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SRT1720 hydrochloride, 5MG
MW 506 Da, Purity >=98%. Selective SIRT1 activator (EC₅₀ = 0.16 μM), 230-fold less potent for SIRT2 and SIRT3. Induce autophagy.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Miglustat hydrochloride, 1MG
MW 255.74 Da, Purity >=98%. An inhibitor of the N-linked oligosaccharide processing enzymes α-glucosidase I and II. It inhibits rat testicular enzymes ceramide-glucosyltransferase and beta-glucosidase 2 with IC₅₀ values of 32 and 81 μM respectively. Miglustat is used for the treatment of type 1 Gaucher's disease. It is an inhibitor of HIV replication in vitro. It shows activity against SARS-CoV-2 in vitro with EC₅₀ values in the micromolar range.
The product is subject to the following: Abcam Restricted Use Statement
Abcam GW-311616A, 5MG
MW 434 Da, Purity >=98%. A potent and selective intracellular neutrophil elastase (NE, alpha-1-proteinase) inhibitor. Inhibits human neutrophil elastase (HNE) and is selective over other human serine proteases with IC₅₀ values of 22 nM for HNE, >100 μM for trypsin, cathepsin G and plasmin, >3 μM for chymotrypsin and tissue plasminogen activator.
The product is subject to the following: Abcam Restricted Use Statement
Abcam GSK-690693 hydrochloride, ATP-competitive pan-Akt kinase inhibitor, 5MG
MW 425.5 Da, Purity >99%. Novel ATP-competitive pan-Akt kinase inhibitor (IC₅₀ values are 2, 13 and 9 nM for Akt1, 2 and 3 respectively). Also exhibits some inhibition of AMPK, PKA and PAK and PKC isoforms (IC₅₀ < 100 nM). Displays antiproliferative and apoptotic effects in tumor cell lines.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Elvitegravir, quinolone HIV integrase inhibitor, 50MG
MW 447.9 Da, Purity >99%. Elvitegravir is an inhibitor of HIV integrase. It inhibits HIV integrase from HIV 1 IIIB (IC₅₀ = 0.7 nM), HIV 2 EHO (IC₅₀ = 2.8 nM) and HIV-2 ROD (IC₅₀ = 1.1 nM) in cell free assays. Elvitegravir blocks integration of HIV cDNA via inhibition of DNA strand transfer. Active against a range of HIV sub-types and against mulit-drug resistant clinical isolates. Potent (IC₅₀ range = 0.21 - 1.15 nM) HIV antiviral activity in various cell-based assays.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Ispinesib (SB-715992), 10MG
MW 517.1 Da, Purity >98%. A potent, selective and reversible allosteric inhibitor of KSP with IC₅₀ value of 0.5 nM. Often combines with chemotherapy drugs to tumor treatment.
The product is subject to the following: Abcam Restricted Use Statement
Abcam IWP-4, 10MG
MW 496.6 Da, Purity >98%. Potent inhibitor of Wnt pathway regulatory protein porupine (Porcn). Blocks Wnt protein secretion and prevents the canonical and non-canonical signaling pathways. Blocks palmitylation, and subsquent secretion and activity of Wnt. Induces differentiation of cardiomyocytes from human ESCs and iPSCs.
The product is subject to the following: Abcam Restricted Use Statement
Abcam BIIB 021, 25MG
MW 318.76 Da, Purity >98%. Selective, Hsp90 competitive inhibitor (Ki = 1.7 nM). Displays no significant activity at a range of ATP-binding kinases or Na+K+ ATPase. Induces degradation of HER-2 in vitro (EC₅₀ = 38 nM in MCF-7 cells). Inhibits growth and promotes cell death in a variety of human tumor cells. Orally bioavailable.
The product is subject to the following: Abcam Restricted Use Statement